AI Assistant
Blog
Pricing
Log In
Sign Up
Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.